Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and Those with Cholestatic Drug Induced Liver Injury

Overview

Journal Am J Gastroenterol

Specialty Gastroenterology

Date 2015 Sep 9

PMID 26346867

Citations 34

Authors

Robert J Fontana

Paul H Hayashi

Huiman Barnhart

David E Kleiner

K Rajender Reddy

Naga Chalasani

William M Lee

Andrew Stolz

Thomas Phillips

Jose Serrano

Paul B Watkins

Affiliations

Soon will be listed here.

Abstract

Objectives: The long-term outcomes of patients with drug induced liver injury (DILI) are not well described. The aim of this study was to determine the frequency and severity of persistent liver biochemistry abnormalities in DILI patients followed over 2 years.

Methods: Subjects with evidence of liver injury at 6 months after DILI onset were offered a month 12 and 24 study visit.

Results: Amongst the 99 patients with definite, probable, or very likely DILI and available laboratory data at 12 months after DILI onset, 74 (75%) had persistent liver injury (persisters) defined as a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 × upper limit of normal (ULN) or an alkaline phosphatase >ULN, while 25 (25%) had resolved liver injury (resolvers). On multivariate analysis, month 12 persisters were significantly older (52.6 vs. 43.7 years, P=0.01) and more likely to have a cholestatic lab profile at DILI onset (54 vs. 20%, P<0.01) than resolvers. The month 12 persisters also had significantly poorer SF-36 physical summary scores at DILI onset and throughout follow-up compared with the resolvers (P<0.01). Amongst the 17 subjects with a liver biopsy obtained at a median of 387 days after DILI onset, 9 had chronic cholestasis, 3 had steatohepatitis, and 3 had chronic hepatitis.

Conclusions: In all, 75% of subjects with liver injury at 6 months after DILI onset have laboratory evidence of persistent liver injury during prolonged follow-up. Higher serum alkaline phosphatase levels at presentation and older patient age were independent predictors of persistent liver injury. Subjects with persistent liver injury at 12 months after DILI onset should be carefully monitored and assessed for liver disease progression.

Citing Articles

Drug-Induced Liver Injury in Patients With Chronic Liver Disease.

Ghabril M, Vuppalanchi R, Chalasani N Liver Int. 2025; 45(3):e70019.

PMID: 39927421 PMC: 11808633. DOI: 10.1111/liv.70019.

Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury.

Liu Q, Huang L, Yan H, Zong Z, Chen Z, Wu X Front Pharmacol. 2024; 15:1406454.

PMID: 39108745 PMC: 11300277. DOI: 10.3389/fphar.2024.1406454.

Yu S, Li J, He T, Zheng H, Wang S, Sun Y Hepatol Int. 2024; 18(4):1202-1213.

PMID: 38898191 PMC: 11297843. DOI: 10.1007/s12072-024-10679-1.

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.

Mao Y, Ma S, Liu C, Liu X, Su M, Li D Hepatol Int. 2024; 18(2):384-419.

PMID: 38402364 DOI: 10.1007/s12072-023-10633-7.

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM.

Kobayashi T, Iwaki M, Nogami A, Yoneda M J Clin Transl Hepatol. 2023; 11(5):1239-1245.

PMID: 37577239 PMC: 10412691. DOI: 10.14218/JCTH.2022.00067S.

References

Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View

Bjornsson E, Davidsdottir L . The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009; 50(3):511-7. DOI: 10.1016/j.jhep.2008.10.021. View

Bjornsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R . Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther. 2007; 26(1):79-85. DOI: 10.1111/j.1365-2036.2007.03355.x. View

Andrade R, Lucena M, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K . Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology. 2006; 44(6):1581-8. DOI: 10.1002/hep.21424. View

Feng S, Goodrich N, Bragg-Gresham J, Dykstra D, Punch J, DebRoy M . Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006; 6(4):783-90. DOI: 10.1111/j.1600-6143.2006.01242.x. View

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

Ware Jr J, Bayliss M, Mannocchia M, Davis G . Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999; 30(2):550-5. DOI: 10.1002/hep.510300203. View

Aithal P, Day C . The natural history of histologically proved drug induced liver disease. Gut. 1999; 44(5):731-5. PMC: 1727509. DOI: 10.1136/gut.44.5.731. View

Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R . Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 1994; 20(6):1437-41. DOI: 10.1002/hep.1840200610. View

10.

Davies M, Harrison R, Elias E, Hubscher S . Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994; 20(1):112-6. DOI: 10.1016/s0168-8278(05)80476-3. View

11.

Levy C, Lindor K . Drug-induced cholestasis. Clin Liver Dis. 2003; 7(2):311-30. DOI: 10.1016/s1089-3261(03)00032-1. View

12.

Ostapowicz G, Fontana R, Schiodt F, Larson A, Davern T, Han S . Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137(12):947-54. DOI: 10.7326/0003-4819-137-12-200212170-00007. View

13.

Saxena R, Hytiroglou P, Thung S, Theise N . Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol. 2002; 33(10):983-8. DOI: 10.1053/hupa.2002.128060. View

14.

Seeff L, Hollinger F, Alter H, Wright E, Cain C, Buskell Z . Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001; 33(2):455-63. DOI: 10.1053/jhep.2001.21905. View

15.

Wiese M, Berr F, Lafrenz M, Porst H, Oesen U . Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. 2000; 32(1):91-6. DOI: 10.1053/jhep.2000.8169. View

16.

Chalasani N, Fontana R, Bonkovsky H, Watkins P, Davern T, Serrano J . Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135(6):1924-34, 1934.e1-4. PMC: 3654244. DOI: 10.1053/j.gastro.2008.09.011. View

17.

Rockey D, Seeff L, Rochon J, Freston J, Chalasani N, Bonacini M . Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010; 51(6):2117-26. PMC: 3249230. DOI: 10.1002/hep.23577. View

18.

Fontana R, Ellerbe C, Durkalski V, Rangnekar A, Reddy R, Stravitz T . Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int. 2014; 35(2):370-80. PMC: 4291312. DOI: 10.1111/liv.12632. View

19.

Fontana R, Hayashi P, Gu J, Reddy K, Barnhart H, Watkins P . Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014; 147(1):96-108.e4. PMC: 4285559. DOI: 10.1053/j.gastro.2014.03.045. View

20.

Kleiner D, Chalasani N, Lee W, Fontana R, Bonkovsky H, Watkins P . Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2013; 59(2):661-70. PMC: 3946736. DOI: 10.1002/hep.26709. View